Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum, and Pediatrics (FrSADP3) - PROGRAM SUMMARY This proposal “Forefronts in Substance Abuse Disorders during Pregnancy, Postpartum and Pediatrics (FrSADP3)” requests its first renewal within NIDA’s Research Education Program. The primary rationale is that there are too few underrepresented minority (URM) clinicians and clinical researchers, too few clinical and research programs investigating substance use (SU) and abuse (SA), and especially, substance abuse disorders (SAD) during pregnancy, postpartum, and in pediatrics (P3); there are far too few new URM trainees for clinical and clinical research careers within the SADP3 fields. Many innovations include optimizing the depth, breadth, and scope of SAD topics of concern during and following pregnancy and the leadership and participation of Indigenous Americans. Our objectives are to train, mentor, provide meaningful research experiences for and help launch the clinical careers of SAD Clinicians and Clinical Scientists (R25 Clinical Trainees). FrSADP3 includes PI and Program Director Gerald Schatten, PhD, at Pitt and Co- I Aimee McRae- Clark, PharmD, BCPP (Addiction Research Leader), with Theresa Cronan, PhD, at SDSU (Facilitator, Psychologist, URM and Women’s Health), Calvin Simerly, PhD, at Pitt (Program Coordinator), and Evan Snyder, MD, PhD, at SBP (Addiction Neonatologist). It is overseen by a Scientific Advisory Board, 40% who are URM faculty. Five Specific Aims: I. Annual FrSADP3 advanced hands-on lab courses, offered at a URM Institution at which we provide conceptual education, expert guided discussions and research training in the methods necessary for studying pregnant people with or at risk for SAD and their neonates, toddlers, and children; relevant animals that self-administer drugs; and the mechanisms of and therapeutic strategies to alleviate the suffering from SADP3, along with research resources available at NIDA and elsewhere. II. Mentored Research into substance use and abuse disorders during pregnancy, postpartum and pediatrics, launched by the participant, together with any FrSADP3 faculty member. III. Encourage trainees’ longer-term Career Planning and gently exploring their self-identified career choices, particularly within the possibilities of them joining NIDA-NIH’s clinical and research workforce. IV. Demystify the changing regulatory oversight requirements in Responsible Conduct for Research (RCR) to ensure full compliance with the NIH’s guidance. V. Unbiased, Quantitative Independent Evaluations to track participants’ careers. The R25’s goals, then, are to provide courses in skills development, mentored addiction research, and ongoing career support resulting in comprehensive, sophisticated training in clinical and translational strategies for addressing the current challenges in addiction during pregnancy, for designing better therapies for the future, and for launching and sustaining successful careers in substance abuse, pregnancy, pediatrics, and related fields. In so doing, FrSADP3 will continue to advance the careers of the most promising clinical scientists and clinicians, with sensitivity for ensuring full diversity in the NIDA workforce.